XML 176 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Segmental information - Consolidated income statement (Details) - GBP (£)
£ in Millions
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Disclosure of operating segments [line items]      
Sales £ 22,448 £ 19,153 £ 17,697
Net sales      
At budgeted exchange rates 15,411 13,483 11,579
Acquisitions and disposals 75 35 93
SC&P allocation 0 0 0
Retranslation to actual exchange rates (223) (785) 80
Hyper Related Adjustment In Respect Of Net Sales 189    
Net sales 15,452 12,733 11,752
Operating profit/(loss)      
At budgeted exchange rates 4,773 4,160 3,498
Acquisitions and disposals (27) (21) (5)
SC&P allocation 0 0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 65 (36)  
Fair value remeasurement of contingent consideration     (7)
Fair value remeasurement of biological assets (5)   9
Retranslation to actual exchange rates (19) (357) (1)
Hyperinflation 10    
Operating profit/(loss) before exceptional items 4,797 3,746 3,494
Exceptional items (388) (15) (1,357)
Operating profit/(loss) 4,409 3,731 2,137
Non-operating items (17) 14 (23)
Net finance charges (422) (373) (353)
Share of after tax results of associates and joint ventures      
Share of after tax results of associates and joint ventures 417 334 282
Profit before taxation £ 4,387 3,706 2,043
Annual net sales occur in the last four months 37.00%    
Moet Hennessy      
Net sales      
Net sales £ 5,553 4,819 4,425
Share of after tax results of associates and joint ventures      
Share of after tax results of associates and joint ventures 425 335 285
Other      
Share of after tax results of associates and joint ventures      
Share of after tax results of associates and joint ventures (8) (1) (3)
Operating segments      
Disclosure of operating segments [line items]      
Sales 22,394 19,133 17,659
Net sales      
At budgeted exchange rates 15,356 13,463 11,541
Acquisitions and disposals 75 35 93
SC&P allocation 0 0 (1)
Retranslation to actual exchange rates (222) (785) 81
Hyper Related Adjustment In Respect Of Net Sales 189    
Net sales 15,398 12,713 11,714
Operating profit/(loss)      
At budgeted exchange rates 5,029 4,378 3,650
Acquisitions and disposals (27) (21) (5)
SC&P allocation 0 0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 65 (36)  
Fair value remeasurement of contingent consideration     (7)
Fair value remeasurement of biological assets (5)   9
Retranslation to actual exchange rates (37) (367) (6)
Hyperinflation 10    
Operating profit/(loss) before exceptional items 5,035 3,954 3,641
Exceptional items (388) (15) (1,357)
Operating profit/(loss) 4,647 3,939 2,284
Operating segments | North America      
Disclosure of operating segments [line items]      
Sales 6,682 5,803 5,222
Net sales      
At budgeted exchange rates 5,955 5,527 4,445
Acquisitions and disposals 34 28 32
SC&P allocation 9 9 11
Retranslation to actual exchange rates 97 (355) 135
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 6,095 5,209 4,623
Operating profit/(loss)      
At budgeted exchange rates 2,388 2,469 2,007
Acquisitions and disposals (28) (18) (1)
SC&P allocation (1) (30) 6
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 32 (9)  
Fair value remeasurement of contingent consideration     (10)
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates 63 (175) 32
Hyperinflation 0    
Operating profit/(loss) before exceptional items 2,454 2,237 2,034
Exceptional items (1) 0 54
Operating profit/(loss) 2,453 2,237 2,088
Operating segments | Europe      
Disclosure of operating segments [line items]      
Sales 5,740 4,795 4,697
Net sales      
At budgeted exchange rates 3,258 2,579 2,501
Acquisitions and disposals 23 2 10
SC&P allocation 46 45 60
Retranslation to actual exchange rates (304) (68) (4)
Hyper Related Adjustment In Respect Of Net Sales 189    
Net sales 3,212 2,558 2,567
Operating profit/(loss)      
At budgeted exchange rates 1,086 728 730
Acquisitions and disposals 11 (3) (4)
SC&P allocation (18) (32) 26
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 36 (27)  
Fair value remeasurement of contingent consideration     (4)
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates (108) (31) 9
Hyperinflation 10    
Operating profit/(loss) before exceptional items 1,017 635 757
Exceptional items (146) (15) (62)
Operating profit/(loss) 871 620 695
Operating segments | Asia Pacific      
Disclosure of operating segments [line items]      
Sales 5,624 5,146 4,645
Net sales      
At budgeted exchange rates 2,879 2,561 2,253
Acquisitions and disposals 0 0 1
SC&P allocation 9 9 12
Retranslation to actual exchange rates (4) (82) 4
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 2,884 2,488 2,270
Operating profit/(loss)      
At budgeted exchange rates 703 628 498
Acquisitions and disposals 0 0 0
SC&P allocation (2) (5) 6
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 0 0  
Fair value remeasurement of contingent consideration     0
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates 10 (15) (3)
Hyperinflation 0    
Operating profit/(loss) before exceptional items 711 608 501
Exceptional items (241) 0 (1,198)
Operating profit/(loss) 470 608 (697)
Operating segments | Africa      
Disclosure of operating segments [line items]      
Sales 2,403 2,020 1,911
Net sales      
At budgeted exchange rates 1,699 1,541 1,300
Acquisitions and disposals 15 5 50
SC&P allocation 3 3 4
Retranslation to actual exchange rates (35) (137) (8)
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 1,682 1,412 1,346
Operating profit/(loss)      
At budgeted exchange rates 346 228 116
Acquisitions and disposals (10) 0 0
SC&P allocation (1) (3) 2
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 0 0  
Fair value remeasurement of contingent consideration     0
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates (20) (54) (17)
Hyperinflation 0    
Operating profit/(loss) before exceptional items 315 171 101
Exceptional items 0 0 (145)
Operating profit/(loss) 315 171 (44)
Operating segments | Latin America and Caribbean      
Disclosure of operating segments [line items]      
Sales 1,945 1,369 1,184
Net sales      
At budgeted exchange rates 1,486 1,176 944
Acquisitions and disposals 3 0 0
SC&P allocation 12 13 10
Retranslation to actual exchange rates 24 (143) (46)
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 1,525 1,046 908
Operating profit/(loss)      
At budgeted exchange rates 528 422 254
Acquisitions and disposals 0 0 0
SC&P allocation 0 (27) 5
Fair value remeasurement of contingent considerations, equity option and earn out arrangements (3) 0  
Fair value remeasurement of contingent consideration     7
Fair value remeasurement of biological assets (5)   9
Retranslation to actual exchange rates 18 (92) (27)
Hyperinflation 0    
Operating profit/(loss) before exceptional items 538 303 248
Exceptional items 0 0 (6)
Operating profit/(loss) 538 303 242
Operating segments | SC&P      
Disclosure of operating segments [line items]      
Sales 2,010 1,537 1,343
Net sales      
At budgeted exchange rates 2,095 1,627 1,439
Acquisitions and disposals 0 0 0
SC&P allocation (79) (79) (98)
Retranslation to actual exchange rates (6) (11) 2
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 2,010 1,537 1,343
Operating profit/(loss)      
At budgeted exchange rates (22) (97) 45
Acquisitions and disposals 0 0 0
SC&P allocation 22 97 (45)
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 0 0  
Fair value remeasurement of contingent consideration     0
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates 0 0 0
Hyperinflation 0    
Operating profit/(loss) before exceptional items 0 0 0
Exceptional items 0 0 0
Operating profit/(loss) 0 0 0
Elimination of intersegment sales      
Disclosure of operating segments [line items]      
Sales (2,010) (1,537) (1,343)
Net sales      
At budgeted exchange rates (2,016) (1,548) (1,341)
Acquisitions and disposals 0 0 0
SC&P allocation 0 0 0
Retranslation to actual exchange rates 6 11 (2)
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales (2,010) (1,537) (1,343)
Corporate and other      
Disclosure of operating segments [line items]      
Sales 54 20 38
Net sales      
At budgeted exchange rates 55 20 38
Acquisitions and disposals 0 0 0
SC&P allocation 0 0 1
Retranslation to actual exchange rates (1) 0 (1)
Hyper Related Adjustment In Respect Of Net Sales 0    
Net sales 54 20 38
Operating profit/(loss)      
At budgeted exchange rates (256) (218) (152)
Acquisitions and disposals 0 0 0
SC&P allocation 0 0 0
Fair value remeasurement of contingent considerations, equity option and earn out arrangements 0 0  
Fair value remeasurement of contingent consideration     0
Fair value remeasurement of biological assets 0   0
Retranslation to actual exchange rates 18 10 5
Hyperinflation 0    
Operating profit/(loss) before exceptional items (238) (208) (147)
Exceptional items 0 0 0
Operating profit/(loss) £ (238) £ (208) £ (147)